Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2019-06-12 Regulatory Filings
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Change in substantial holding 5 pages 317.8KB
Regulatory Filings
2019-06-12 English
Response to ASX Query 5 pages 953.5KB
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from Genetic Technologies Limited (GTG) to the ASX (Australian Securities Exchange) regarding a late lodgement of an Appendix 3Y, which is a Change of Director's Interest Notice. The letter addresses compliance with ASX Listing Rules 3.19A and 3.19B concerning director securities trading disclosures. It includes explanations about the late filing, internal policies, and remedial actions proposed by the company. The document is regulatory in nature, dealing with compliance and disclosure obligations rather than financial results, management changes, or shareholder votes. It is not a financial report, earnings release, or management discussion. It is also not a simple announcement but a formal regulatory response to an ASX query. Therefore, the document fits best under Regulatory Filings (RNS), which covers compliance documents and regulatory announcements that do not fit other categories.
2019-06-10 English
Change of Director's Interest Notice Mr Lee 2 pages 249.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares disposed and acquired, dates of changes, and nature of the transactions. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial performance data, management discussion, or regulatory announcements unrelated to director dealings. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 4206 characters, consistent with a detailed insider trading notice rather than a full financial report or announcement.
2019-06-04 English
Correction to Appendix 3B issued 6 May 2019 18 pages 980.0KB
Share Issue/Capital Change Classification · 100% confidence The document is an ASX Market Announcement dated 4 June 2019, titled 'CORRECTION TO 6 MAY 2019 APPENDIX 3B'. It refers to an Appendix 3B form, which is a 'New issue announcement, application for quotation of additional securities and agreement' under ASX Listing Rules. The content includes detailed information about securities issued, issue capacity under ASX Listing Rules 7.1 and 7.1A, and other related details about the securities and quotation agreement. Appendix 3B is a standard form used for announcements related to new share issues or capital changes. The document is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes and securities issuance. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is substantial (15,000 characters), and it contains the full announcement, not just a notice of publication, so it is not an RPA or RNS filing.
2019-06-03 English
Change in substantial holding 5 pages 311.1KB
Regulatory Filings
2019-06-02 English
Change in substantial holding 5 pages 177.7KB
Regulatory Filings
2019-05-26 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.